For years, oncologists have wrestled with the partial efficacy of checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo). While these agents can unleash T‑cell responses against melanoma, lung cancer, and other malignancies, many patients never respond or experience a relapse after an initial period of benefit. The underlying cause has been elusive, suggesting an internal mechanism by which tumors evade an activated immune system.
A landmark study published in Nature on June 9 2026 by Dr. André Veillette and colleagues at the Université de Montréal and the Montreal Clinical Research Institute has identified SLAMF6—Signaling Lymphocytic Activation Molecule 6—as a previously undercharacterized receptor on T cells that functions as an autonomous, self‑activating brake on anti‑cancer activity.
Mechanism and Significance of SLAMF6
Conventional checkpoint inhibitors block tumor‑derived signals that down‑regulate T‑cell function. For example, tumor‑expressed PD‑L1 binds PD‑1 on T cells; blockade of this interaction by pembrolizumab releases the brake. CTLA‑4 operates through a similar principle.
SLAMF6 differs fundamentally. It is activated through homotypic interactions on the T‑cell surface—binding to identical molecules on the same or neighboring cells—without requiring external signals from the tumor. Consequently, SLAMF6 suppresses T‑cell activity regardless of tumor ligand expression, a phenomenon that likely underlies resistance in many cancers that fail to respond to PD‑1 or CTLA‑4 blockade.
SLAMF6 is predominantly expressed on progenitor or stem‑like exhausted T cells, the subset that retains the capacity for functional restoration after checkpoint inhibition. By attenuating this critical population through a tumor‑independent mechanism, SLAMF6 curtails immune responses both within the tumor microenvironment and before T cells fully engage the malignancy.
To counteract SLAMF6’s inhibitory effects, Veillette’s team engineered monoclonal antibodies that prevent SLAMF6 from binding to itself. In murine tumor models, these antibodies achieved markedly superior tumor‑reduction compared to existing SLAMF6‑targeting approaches and displayed encouraging synergy when combined with PD‑1 inhibitors.
“By uncovering an internal brake that had remained unrecognized and by developing antibodies to neutralize it, our researchers are offering an innovative solution to the limitations of current therapies,” noted Dr. Jean‑François Côté, president and scientific director of IRCM.
Path Toward Clinical Application
SLAMF6‑targeted antibodies are presently in preclinical development. Human trials typically commence 3 to 5 years after promising animal data, following Phase I safety assessments. Because SLAMF6 acts independently of tumor‑specific expression, this discovery has the potential to broaden therapeutic applicability across a wider spectrum of solid tumors than current checkpoint inhibitors—including the roughly 40–50 % of cancers that respond inadequately to PD‑1 and CTLA‑4 blockade.
Frequently Asked Questions
Q: What is SLAMF6?
A: SLAMF6 is a receptor on T‑cell surfaces that, when it binds to another copy of itself, delivers a self‑regulatory ‘stop’ signal that dampens the T‑cell’s anti‑tumor activity. This function is independent of signals from tumor cells.
Q: How does SLAMF6 differ from existing immunotherapy targets?
A: PD‑1 and CTLA‑4 inhibitors neutralize tumor‑derived signals that suppress T cells. In contrast, SLAMF6 self‑activates on T cells without any tumor input, thereby suppressing immunity in cancers that evade conventional checkpoint blockade.
Q: Are SLAMF6‑targeting drugs available?
A: No. The research is at the preclinical stage as of June 2026. Human clinical trials are expected within 3–5 years, contingent on further development.
Q: Which cancers might benefit?
A: SLAMF6’s tumor‑independent mechanism suggests potential benefits across many solid tumors, especially those that do not respond well to existing checkpoint inhibitors. Specific tumor types are under investigation.